Gilead's Bictegravir Data Could Mean Continued HIV Sector Dominance

Phase II data presented at CROI aren't sufficient to demonstrate statistical superiority over ViiV's Tivicay, but one analyst predicts that a repeat performance in larger Phase III trials could support a superiority claim.